EGFR, HER2 & Receptor Tyrosine Kinases

Cat. No.

AT0688

CAS No.

2517935-02-1

Fazpilodemab

Synonyms: BFKB8488A; RG-7992; RO-7040551

Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody designed to specifically target fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. This antibody is engineered for the investigation of metabolic disorders, particularly type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Fazpilodemab's dual targeting mechanism facilitates the study of signaling pathways that may play critical roles in the pathophysiology of these conditions.

Cat. No.

AT0755

CAS No.

2438203-51-9

Barzolvolimab

Synonyms: CDX-0159; CDX-0158

Barzolvolimab (CDX 0159) is a humanized IgG1 monoclonal antibody targeting the KIT receptor. It demonstrates specificity and potent inhibition of KIT activation mediated by the stem cell factor (SCF). Clinically, Barzolvolimab has been shown to effectively reduce skin mast cell populations and alleviate disease activity in chronic inducible urticaria, highlighting its potential therapeutic application in related pathologies.

Cat. No.

AT0761

CAS No.

946832-34-4

Racotumomab

Synonyms: 1E10

Racotumomab is a recombinant anti-idiotype monoclonal antibody that targets Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other tumor-associated antigens. This antibody has demonstrated efficacy as an active anticancer agent, particularly in the treatment of lung cancer. Its specificity for NeuGc epitopes makes it a valuable tool for research and therapeutic applications in oncology.

Cat. No.

AT0782

CAS No.

934235-44-6

Robatumumab

Synonyms: Sch 717454; 19D12

Robatumumab (Sch 717454) is a monoclonal antibody targeting the insulin-like growth factor receptor-1 (IGF-1R). It exhibits potent anti-tumor and anti-proliferative effects on cancer cells. This antibody is particularly relevant for research in osteosarcoma and Ewing sarcoma, providing a valuable tool for investigating the role of IGF-1R in cancer pathogenesis and therapy.

Cat. No.

AT0789

CAS No.

2362015-67-4

Lonigutamab

Synonyms: hz208F2-4

Lonigutamab (hz208F2-4) is a humanized monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R). This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), offering potential applications in targeted cancer therapy.

Cat. No.

AT0812

CAS No.

339177-26-3

Panitumumab

Synonyms: ABX-EGF

Panitumumab (ABX-EGF) is a fully human IgG2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), exhibiting potent anti-tumor properties. This antibody effectively inhibits tumor cell proliferation, survival, and angiogenesis, making it a valuable tool for cancer research, particularly in studies focused on colon cancer.

Cat. No.

AT0821

Anti-c-Met/HGFR Antibody

The Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody specifically designed to target the c-Met receptor, also known as hepatocyte growth factor receptor (HGFR). This antibody is recommended for use with Human IgG1 kappa as an isotype control to ensure specificity and accuracy in experimental results.

Cat. No.

AT0822

Anti-EphB4 Antibody

Cat. No.

AT0826

CAS No.

1005389-60-5

Dalotuzumab

Synonyms: MK-0646; h7C10

Dalotuzumab (MK-0646) is a recombinant humanized IgG1 monoclonal antibody designed to specifically target the insulin-like growth factor 1 receptor (IGF-1R). This antibody functions by inhibiting the signaling pathways initiated by IGF-1 and IGF-2, which are commonly implicated in tumor cell proliferation. It effectively blocks IGF-1R autophosphorylation and subsequent phosphorylation of Akt, a critical node in the pro-survival signaling network. Additionally, Dalotuzumab promotes apoptosis and induces cell cycle arrest, further inhibiting cancer cell growth. Research has demonstrated that when used in conjunction with other anticancer agents, including statins, Dalotuzumab exhibits enhanced antitumor efficacy both in vitro and in vivo. This makes it a valuable tool for studies focused on cancer biology and therapeutic antibody development.

Cat. No.

AT0841

CAS No.

1365287-97-3

Emibetuzumab

Synonyms: LY2875358

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody of the IgG4 subtype, designed to exhibit potent neutralizing and internalizing capabilities. This antibody effectively inhibits both hepatocyte growth factor (HGF)-dependent and HGF-independent MET pathway activations, thereby impeding tumor growth. Emibetuzumab is primarily utilized in cancer research studies, focusing on its therapeutic potential and mechanism of action in oncogenic signaling and tumor progression.

Cat. No.

AT0845

CAS No.

2559704-24-2

Izalontamab

Synonyms: SI-B001

Izalontamab (SI-B001) is a bispecific monoclonal antibody designed to selectively target the EGFR/HER3 heterodimer, demonstrating high specificity in its binding affinity. This antibody is primarily utilized in cancer research, facilitating the study of molecular pathways and potential therapeutic interventions related to EGFR and HER3 interactions.

Cat. No.

AT0849

CAS No.

1634620-63-5

Aprutumab

Synonyms: BAY 1179470

Aprutumab (BAY 1179470) is a fully human monoclonal antibody targeting the fibroblast growth factor receptor 2 (FGFR2). It exhibits specific binding affinity to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. This antibody is primarily explored for its applicability in the study of solid tumors, offering significant potential for research into cancer biology and therapeutic development.

Cat. No.

AT0850

CAS No.

2574591-89-0

Briquilimab

Synonyms: JSP-191

Briquilimab (JSP-191) is a humanized monoclonal antibody engineered to target CD117 (c-Kit), facilitating the depletion of hematopoietic stem cells (HSCs). This antibody is characterized by its non-toxic profile, making it an ideal agent for clearing host marrow niche spaces. The primary application of Briquilimab is to enhance donor HSC engraftment and promote immune reconstitution, particularly in the treatment of severe combined immunodeficiency (SCID). This mechanism not only supports effective hematopoietic transplantation but also ensures safety and efficacy in clinical settings.

Cat. No.

AT0872

Petosemtamab (FUT8-KO)

Petosemtamab is a dual-target monoclonal antibody that selectively binds to both epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). Expressed in Chinese hamster ovary (CHO) cells genetically engineered to lack the fucosyltransferase 8 gene (FUT8), this modification results in a fucose-deficient antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). With dissociation constants (Kd) of 0.22 nM for EGFR and 0.86 nM for LGR5, Petosemtamab effectively inhibits EGFR signaling and induces receptor degradation in LGR5-positive cancer cells. This antibody is particularly relevant for research into solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for studies aimed at understanding and potentially intervening in the pathways involved in these malignancies.

Cat. No.

AT0883

CAS No.

2437210-79-0

Bafisontamab

Synonyms: EMB-01

Bafisontamab (EMB-01) is a bispecific monoclonal antibody designed for targeted cancer therapy. It simultaneously binds to the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (c-MET), exhibiting potent antitumor activity. This dual targeting mechanism disrupts critical pathways involved in tumor growth and survival, making Bafisontamab a valuable tool for research in oncology.

Cat. No.

AT0904

Anti-HGFR/c-Met Antibody

Cat. No.

AT0975

CAS No.

2750004-05-6

Pamvatamig

Pamvatamig is a human IgG4 κ monoclonal antibody that targets both EGFR and MET receptors. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for the study of signal transduction pathways and may be useful in research focused on cancer biology where EGFR and MET play critical roles.

Cat. No.

AT0977

CAS No.

780758-10-3

Nimotuzumab

Nimotuzumab is a humanized IgG1 monoclonal antibody engineered to target the epidermal growth factor receptor (EGFR) with a dissociation constant (K_D) of 0.21 nM. This antibody specifically binds to the extracellular domain of EGFR, effectively inhibiting the receptor's interaction with its natural ligands. Nimotuzumab exhibits potent antitumor activity, primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This mechanism facilitates the targeted destruction of tumor cells, underscoring its utility in oncological research and therapeutic applications.

Cat. No.

AT0979

CAS No.

1622327-38-1

Laprituximab

Synonyms: J2898A

Laprituximab (J2898A) is a humanized IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This antibody serves as a precursor for the synthesis of the antibody-drug conjugate (ADC) IMGN289, utilized in targeted cancer therapy research.

Cat. No.

AT0999

CAS No.

1262787-83-6

Patritumab

Synonyms: Human Anti-ERBB3 Recombinant Antibody

Patritumab is a recombinant human monoclonal antibody that specifically targets ERBB3, exhibiting neutralizing properties. This antibody effectively synergizes with Cetuximab to inhibit the phosphorylation of key signaling proteins including EGFR, HER2, HER3, ERK, and AKT. Through its action, Patritumab induces apoptosis and inhibits tumor growth, demonstrating significant efficacy in preclinical models of pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Patritumab is a valuable tool for research focused on the molecular mechanisms of cancer progression and therapeutic antibody development.

Cat. No.

AT1001

CAS No.

1204390-13-5

Dusigitumab

Synonyms: MEDI 573

Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody engineered to specifically bind to both IGF1 and IGF2. This targeted interaction potentially modulates the activity of these growth factors, which are crucial in cellular processes such as growth, development, and metabolism. Dusigitumab is primarily utilized in research focused on the pathophysiology and therapeutic targeting of diseases influenced by IGF signaling.

Cat. No.

AT1018

CAS No.

943453-46-1

Figitumumab

Synonyms: CP-751871

Figitumumab (CP-751871) is a potent, fully human monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R). This antibody effectively inhibits the binding of IGF1 to IGF1R, demonstrating an inhibitory concentration (IC50) of 1.8 nM. Designed for high specificity and affinity, Figitumumab is utilized primarily in research focused on the modulation of growth factor signaling pathways.

Cat. No.

AT1036

CAS No.

1869928-62-0

Cofetuzumab

Synonyms: PF-06523435; hu24

Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody that specifically targets protein tyrosine kinase 7 (PTK7). This antibody is produced using a Chinese Hamster Ovary (CHO) cell expression system, ensuring high fidelity and stability in the recombinant product. Cofetuzumab is designed for use in research applications focusing on the role of PTK7 in cancer pathogenesis and other related signaling pathways.

Cat. No.

AT1047

CAS No.

2648058-48-2

Davutamig

Synonyms: REGN-5093

Davutamig (REGN-5093) is a human IgG4-kappa monoclonal bispecific antibody designed to target two distinct, non-overlapping epitopes on the MET receptor. This antibody functions as an antineoplastic agent, primarily utilized in cancer research and therapy. Its unique bispecific nature allows for enhanced specificity and efficacy in targeting the MET receptor, a critical player in the pathology of various cancers.

Cat. No.

AT1086

CAS No.

2673271-78-6

Nezutatug

Nezutatug is a monoclonal antibody targeting the human epidermal growth factor receptor 3 (HER3), a protein implicated in the modulation of cell growth and differentiation. This antibody is specifically designed for use in cancer research, where it serves as a crucial tool for studying the role of HER3 in oncogenic processes and potential therapeutic interventions. Nezutatug is suitable for various experimental applications, including flow cytometry, Western blotting, and immunohistochemistry, making it a versatile reagent in the investigation of HER3's function and its involvement in cancer pathogenesis.